Which of these Footsie healthcare stars should you buy after today’s news?

Royston Wild discusses the investment prospects of two Footsie medical giants.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

News of declining earnings has seen private hospital group Mediclinic International (LSE: MDC) fail to keep touch with its FTSE 100 peers in Thursday business, the stock last seen dealing 6% lower on the day.

Mediclinic — which operates medical facilities across South Africa, Switzerland and the United Arab Emirates — announced that underlying earnings per share dropped 26% during April-September, due to the cost of acquiring the Al Noor hospital group.

This is not the first time Mediclinic’s Middle Eastern operations have spooked investors. Indeed, several factors — changes to medical insurance cover in the region, a large number of doctor vacancies, and delayed facility openings, such as that of the Al Jowhara hospital — forced the company to scale back its revenues guidance in September.

Despite these problems, I believe that Mediclinic remains an attractive pick for long-term investors. Indeed, the healthcare giant saw revenues gallop 27% higher during the fiscal first half, to £1.28bn, with Al Noor contributing 16% to this sales growth.

These figures underline the growing need for private healthcare in emerging regions, a phenomenon that looks set to continue as disposable income levels grow. And Mediclinic is also performing extremely well in its traditional markets, too, and enjoyed a solid 5% revenues upswing in Switzerland during the half year.

The City certainly expects sales at Mediclinic to keep charging higher, resulting in earnings growth of 17% and 19% in the years to March 2017 and 2018 respectively.

Consequent P/E ratings of 20.1 times and 16.9 times may be slightly expensive from a ‘classic’ investing perspective — these readings are ahead of the Footsie forward average of 15 times. However, I believe Mediclinic’s white-hot growth prospects warrant this slight premium.

The right medicine?

Medicine maker Hikma Pharmaceuticals (LSE: HIK) has also endured fresh share price losses today, the stock last 3% lower from Wednesday’s session.

Disappointing volume growth at its Generics unit has forced Hikma to announce a downward revision to its 2016 revenues target, the company now expecting full-year sales at the division to clock in at $600m versus its previous target of between $640 and $670m. Consequently Hikma now expects group revenues to come in at between $2bn and $2.1bn, down from its prior guidance of $2bn.

Still, Hikma remains bullish on the long-term prospects of its Generics operations, and expects sales here to shoot to $800m in fiscal 2017 on the back of “market share gains of high value products, portfolio rationalisation and pipeline execution.”

Of course investment in the pharma sector is always fraught with risk — such is the nature of drugs development. But I believe the strength of Hikma’s bubbly product pipeline, not to mention benefits resulting from recent acquisition activity, make it a potentially-explosive growth selection.

The City certainly expects Hikma to recover from its current troubles, and rebound from a 24% earnings decline in 2016 to print a 35% rise next year. With the P/E rating expected to consequently topple from 19.5 times for this year to 14.4 times, I reckon the drugs giant is worthy of serious attention.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Royston Wild has no position in any shares mentioned. The Motley Fool UK has recommended Hikma Pharmaceuticals. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

Just released: November’s small-cap stock recommendation [PREMIUM PICKS]

We believe the UK small-cap market offers a myriad of opportunities across a wide range of different businesses and industries.

Read more »

Man putting his card into an ATM machine while his son sits in a stroller beside him.
Investing Articles

The Barclays share price has soared 72% in 2024. Is it too late for me to buy?

I'm looking for a bank stock to buy in early 2025. The 2024 Barclays share price rise has made the…

Read more »

Investing Articles

2 lessons from the HSBC share price soaring 159% in four years

Christopher Ruane looks at the incredible performance of the HSBC share price in recent years and learns some lessons for…

Read more »

Portrait of elderly man wearing white denim shirt and glasses looking up with hand on chin. Thoughtful senior entrepreneur, studio shot against grey background.
Investing Articles

After a 2,342% rise, could this FTSE 250 stock keep going?

This FTSE 250 stock boasts a highly cash-generative business model and has been flying for years. Is it time to…

Read more »

Investing Articles

It’s up 70%, but the experts expect the IAG share price to climb still further

Why didn't I buy when I was convinced the IAG share price was likely to soar? And is there still…

Read more »

Businessman use electronic pen writing rising colorful graph from 2023 to 2024 year of business planning and stock investment growth concept.
Investing Articles

2 UK stocks with recovering profit margins

This writer considers a pair of UK stocks with very different share price trajectories following the pandemic. Would he buy…

Read more »

The flag of the United States of America flying in front of the Capitol building
Investing Articles

Will Trump’s tariffs squeeze this FTSE 100 giant’s profits?

Our writer looks at how the latest news around US tariffs might impact FTSE 100 company Diageo. Should he be…

Read more »

Investing Articles

Up 95%, is this FTSE winner the best high-yield star for me to buy now?

Do we have to choose between share price growth and high-yield dividends? In this case, over the past year, it…

Read more »